Drug Nanoformulations Research Articles

Facile Engineering of Indomethacin-Induced Paclitaxel Nanocrystal Aggregates as Carrier-Free Nanomedicine with Improved Synergetic Antitumor Activity.

Carrier-free nanomedicines mainly composed of drug nanocrystals are considered as promising candidates for next-generation nanodrug formulations. However, such nanomedicines still need to be stabilized by additive surfactants, synthetic polymers, or biologically based macromolecules. Based on the strong intermolecular interactions between indomethacin (IDM, a COX-2 inhibitor) and paclitaxel (PTX, a chemotherapy drug), we herein successfully engineered a novel kind of carrier-free nanomedicines that organized as IDM-induced PTX nanocrystal aggregates via one-pot self-assembly without any nonactive excipients. In the assemblies of IDM and PTX (IDM/PTX assemblies), PTX nanocrystals were casted with amorphous IDM molecules, like a "brick-cement" architecture. In serum, these nanoassemblies could rapidly collapse into a great number of smaller nanoparticles, thus targeting the tumor site through the EPR effect. Under the assistance of IDM on immunotherapy, the IDM/PTX assemblies showed obviously improved synergetic antitumor effects of immunotherapy and chemotherapy. The self-assembly of two synergistic active substances into nanomedicines without any nonactive excipients might open an alternative avenue and give inspiration to fabricate novel carrier-free nanomedicines in many fields.

Synthesis and encapsulation of V(IV,V) compounds in silica nanoparticles targeting development of antioxidant and antiradical nanomaterials

The quest for effective treatments of oxidative stress has concentrated over the years on new nanomaterials with improved antioxidant and antiradical activity, thereby attracting broad research interest. In that regard, research efforts in our lab were launched to pursue such hybrid materials involving a) synthesis of silica gel matrices, b) evaluation of the suitability of atoxic matrices as potential carriers for the controlled release of V(IV)(VOSO4), V(V)(NaVO3) compounds and a newly synthesized heterometallic lithium-vanadium(IV,V) tetranuclear compound containing vanadium-bound hydroxycarboxylic 1,3-diamine-2-propanol-N,N,N′,N′-tetraacetic acid (DPOT), and c) investigation of structural and textural properties of silica nanoparticles (NPs) by different and complementary characterization techniques, inquiring into the nature of the encapsulated vanadium species and their interaction with the siloxane matrix, collectively targeting novel antioxidant and antiradical nanomaterials biotechnology. The physicochemical characterization of the vanadium-loaded SiO2 NPs led to the formulation of optimized material configuration linked to the delivery of the encapsulated antioxidant-antiradical load. Entrapment and drug release studies showed a) the competence of hybrid nanoparticles with respect to encapsulation efficiency of the vanadium compound (concentration dependence), b) congruence with the physicochemical features determined, and c) a well-defined release profile of NP load. Antioxidant properties and the free radical scavenging capacity of the new hybrid materials (containing VOSO4, NaVO3, and V-DPOT) were demonstrated through a) 2-diphenyl-1-picrylhydrazyl (DPPH) free radical, and b) intracellular-extracellular reactive oxygen species (ROS) assays, through UV–Visible spectroscopy techniques, collectively showing that the hybrid silica NPs (empty-loaded) could serve as an efficient platform for nanodrug formulations counteracting oxidative stress.

Overview on Nanoemulsion as a recently developed approach in Drug Nanoformulation

A new fashion of medication conveyance framework has been industrialized to hinder main imperfections related to the conformist medication conveyance framework. This review gives an idea of covering the knowledge of modern nanoemulsion. Nanoemulsions are an emulsion of nanodroplet manufactured with low and/or high energy techniques to provide a drug in bestead mode. Nanoemulsions are isotropic thermodynamic stable system consist of two immiscible liquids form a monophasic system using emulsifying agents as surfactant and co-surfactant. These vary in the shape and size of the conventional emulsion droplets of the internal phase, since nanoemulsion has a droplet size range from 20 to 200 nm. This review provides constituent information covering its preparation method, formulation, parameters of evaluation, techniques of characterization and nanoemulsion applications.

The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.

The application of nanotechnology in the medical field is called nanomedicine. Nowadays, this new branch of science is a point of interest for many investigators due to the important advances in which we assisted in recent decades, in particular for cancer treatment. Cancer nanomedicine has been applied in different fields such as drug delivery, nanoformulation and nanoanalytical contrast reagents. Nanotechnology may overcome many limitations of conventional approaches by reducing the side effects, increasing tumor drug accumulation and improving the efficacy of drugs. In the last two decades, nanotechnology has rapidly developed, allowing for the incorporation of multiple therapeutics, sensing and targeting agents into nanoparticles (NPs) for developing new nanodevices capable to detect, prevent and treat complex diseases such as cancer. In this review, we describe the main drug nanoformulations based on different types of organic NPs, the advantages that the new formulations present in comparison with their free drug counterparts and how nanodrugs have improved clinical care. We subdivided them into four main groups: polymeric NPs, liposomes, micelles and exosomes, a small subgroup that has only recently been used in clinical trials. The application of nanotechnology to pharmaceutical science has allowed us to build up nanosystems based on at least two stage vectors (drug/nanomaterial), which often shown better pharmacokinetics (PK), bioavailability and biodistribution. As a result of these advantages, the nanomaterials accumulate passively in the tumor (due to the enhanced permeability and retention, effect, EPR), thereby decreasing the side effects of free drug. Recently, many new drug formulations have been translated from bench to bedside. It is important to underline that the translation of nanomedicines from the basic research phase to clinical use in patients is not only expensive and time-consuming, but that it also requires appropriate funding. After many years spent in the design of innovative nanomaterials, it is now the time for the research to take into consideration the biological obstacles that nanodrugs have to overcome. Barriers such as the mononuclear phagocyte system, intratumoral pressure or multidrug resistance are regularly encountered when a cancer patient is treated, especially in the metastatic setting.

A Plug-and-Play, Drug-on-Pillar Platform for Combination Drug Screening Implemented by Microfluidic Adaptive Printing.

Traditional high-throughput drug combination screening requires automatic pipetting of drugs into high-density microtiter plates. Here, a drug-on-pillar platform is proposed for efficient combination drug screening. Using the proposed approach, combination drug screening can be carried out in a plug-and-play manner, allowing for high-throughput screening of large permutations of drug combinations at various concentrations, such that drug dispensing and cell-based screening can be temporally separated and therefore can potentially be performed at distant laboratories. The dispensing is implemented using our recently developed microfluidic pneumatic printing platform, which features a low-cost disposable cartridge that minimizes cross contamination. Moreover, our previously developed drug nanoformulation method with amphiphilic telodendrimers has been utilized to maintain drug stability in a dry form, allowing for convenient drug storage, shipping, and subsequent rehydration. Combining the features described above, we have implemented a 1260-spot drug combination array to study the effect of paired drugs against MDA-MB-231 triple negative human breast cancer cells. This study supports the feasibility of the drug-on-pillar platform for combination drug screening and has provided valuable insight into drug combination efficacy against breast cancer.

Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides.

Over recent decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies—a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to achieve elevated local concentration and extended half-life of the drugs in the peritoneal cavity to improve their anticancer efficacy. However, IP-administered chemotherapeutics have a short residence time in the IP space, and are not tumor selective. An increasing body of work suggests that functionalization of drugs and nanoparticles with targeting peptides increases their peritoneal retention and provides a robust and specific tumor binding and penetration that translates into improved therapeutic response. Here we review the progress in affinity targeting of intraperitoneal anticancer compounds, imaging agents and nanoparticles with tumor-homing peptides. We review classes of tumor-homing peptides relevant for PC targeting, payloads for peptide-guided precision delivery, applications for targeted compounds, and the effects of nanoformulation of drugs and imaging agents on affinity-based tumor delivery.

Hydroxyethyl starch stabilized polydopamine nanoparticles for cancer chemotherapy

Bio-inspired polydopamine (PDA) based nanomaterials, particularly nanoparticles (NPs), received tremendous attention and have been applied to various fields, including drug delivery. Nonetheless, bare PDA NPs will aggregate in physiological conditions and can be hardly applied for in vivo explorations. Herein, we present the preparation of novel hydroxyethyl starch coated PDA (HES-PDA) NPs for cancer chemotherapy. The frequently used PEG-modified PDA (PEG-PDA) NPs are also manufactured as a control and doxorubicin (DOX) is chosen as a model drug. The stability, drug loading capacity, lyophilization and rehydration property, biodistribution, in vitro and in vivo anti-tumor efficacy, and toxicity of DOX-loaded HES-PDA (DOX@HES-PDA NPs) are investigated. Collectively, DOX@HES-PDA NPs, similar to DOX@PEG-PDA NPs, show potent antitumor efficacy and dramatically mitigate toxicity associated with DOX. The HES-PDA NPs reported herein represent a novel biodegradable multifunctional nano-drug formulation, with significant translation potentials, for cancer chemotherapy against a wide spectrum of cancers.

Nanotechnological approaches for the development of herbal drugs in treatment of diabetes mellitus – a critical review

Diabetes mellitus (DM) is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. The number of people with diabetes is increasing due to population growth, ageing, urbanisation and increasing prevalence of obesity and physical inactivity. Apart from currently available therapeutic options, many herbal medicines have been recommended for the treatment of diabetes. Herbal drugs are prescribed widely because of their effectiveness, less side effects and relatively low cost. Several pharmacopoeias have provided parameters to maintain quality and standardise procedures in identification/authentication of herbal inputs and their products. Available literature related to folklore medicine used in the treatment of diabetes extended to nanoformulation of herbal drugs up to date was cited. The use of bioactive compounds leads to new hope to improve the life expectancy and health status of the population for the formulation of novel drugs. Recently, many studies have shown that nanotechnology has the potential to be used in different biological and medical applications, mainly as targeted drug delivery systems to minimise and delay the chronic effects of diabetes. Herein, the authors presented a thorough review of the available herbal medicines and the possibilities of developing their nanoformulations in the treatment of DM.

Cell-derived Exosomes as Promising Carriers for Drug Delivery and Targeted Therapy.

Exosomes are small vesicles that are secreted by various types of cells, known to mediate signal transduction between cells. During recent years, novel carriers for the delivery of targeted drugs, chemotherapy drugs and RNAs are under development, which is believed to be beneficial for patients. Considering issues of drug nano-formulations in bloodstream, such as nano-toxicity and rapid clearance by mononuclear phagocyte system, exosomes derived from either patient's cells or bodyfluids, seem to be an optimal option. This review presents the current patterns of drug-loaded into exosomes and discusses how exosomes were reconstructed for targeted therapy. Loading either exosomes directly or their donor cells is an alternative, including incubation, electroporation, transfection of exosomes or transfection, incubation, activation of the parent cells. To solve the low efficiency of cargo loading into exosomes, protein loading via optically reversible protein-protein interaction can realize a novel exosomal protein carrier. In addition, targeted therapeutics with exosomes is achieved by three means, via adding targeting peptides into the surface of exosomes, by transferring specific genes within exosomes into tumors to establish a therapeutic target and, lastly, by targeting at exosomes containing tumor associated antigens. Nevertheless, purification and mass production of exosomes need further exploration, as well as more approaches were applied to targeted therapy. Therefore, exosomes could serve as an effective tool for drug delivery and targeted therapy.

Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain

Human Immunodeficiency Virus Type 1 (HIV-1) remains one of the leading causes of death worldwide. Present combination antiretroviral therapy has substantially improved HIV-1 related pathology. However, delivery of therapeutic agents to the HIV reservoir organ like Central nervous system (CNS) remains a major challenge primarily due to the ineffective transmigration of drugs through Blood Brain Barrier (BBB). The recent advent of nanomedicine-based drug delivery has stimulated the development of innovative systems for drug delivery. In this regard, particular focus has been given to nanodiamond due to its natural biocompatibility and non-toxic nature–making it a more efficient drug carrier than other carbon-based materials. Considering its potential and importance, we have characterized unmodified and surface-modified (-COOH and -NH2) nanodiamond for its capacity to load the anti-HIV-1 drug efavirenz and cytotoxicity, in vitro. Overall, our study has established that unmodified nanodiamond conjugated drug formulation has significantly higher drug loading capacity than surface-modified nanodiamond with minimum toxicity. Further, this nanodrug formulation was characterized by its drug dissolution profile, transmigration through the BBB, and its therapeutic efficacy. The present biological characterizations provide a foundation for further study of in-vivo pharmacokinetics and pharmacodynamics of nanodiamond-based anti-HIV drugs.

Green silver nanoparticles from novel Brassicaceae cultivars with enhanced antimicrobial potential than earlier reported Brassicaceae members

In the present study, we report perhaps for the first time the use of novel varieties of Brassica oleracea var. botrytis and Raphanus sativus as potential bioreductant, to synthesize highly stable silver nanoparticles (AgNPs, no aggregation observed for six months), which is a significant finding as plant extract-directed AgNPs are intrinsically unstable and tend to aggregate. The reduction of Ag+ to Ag0 nanostructures was confirmed using UVVis spectroscopy showing SPR spectra at 400–435 nm. Nanosight and transmission electron microscope (TEM) analysis showed monodisperse spherical AgNPs (4–18 nm). Fourier transform infrared spectroscopy (FTIR) analysis revealed that the polyphenolics and other secondary metabolites including glucosinolates in the aqueous extracts may act as reducing/capping agent for the nanoparticle synthesis. X-ray diffraction (XRD) confirmed the face centered cubic crystalline (fcc) structure of AgNPs. Controlled synthesis of AgNPs was achieved by varying experimental parameters (AgNO3 concentration, extract volume, pH and temperature). These AgNPs exhibited strong antibacterial activity at significantly lower concentration (5 ppm) against both Gram negative (Escherichia coli, Myroides, Psuedomonas aeruginosa) and Gram positive (Kocuria and Promicromonospora) bacteria. In the present study, the green AgNPs showed (10–30%) better antimicrobial efficacy than chemical AgNPs and AgNPs from other Brassicaceae members. These green AgNPs may have promising application in nano-drug formulation to combat bacterial infections, in future.

LAL test and RPT for endotoxin detection of CPT-11/DSPE-mPEG2000 nanoformulation: What if traditional methods are not applicable?

Endotoxin detection is an important step in drug characterization. Herein we found that a chemotherapeutic drug nanoformulation composed of irinotecan hydrochloride (CPT-11) and an amphiphilic molecule DSPE-mPEG2000 can interfere with the limulus amebocyte lysate assay (LAL). Furthermore, the rabbit pyrogen test (RPT) results indicated that at a relatively high dosage, the drug irinotecan hydrochloride can induce a hypothermia effect which may render the RPT results ambiguous in determination of the safety of the drug formulation.Our findings demonstrate limitations of endotoxin detection in micellar drugs, and call for the necessity of developing reliable endotoxin detection methods that can overcome the interference of nanomaterials in order to better ensure the drug safety of patients in future pharmaceutical drug development.

Management of Chronic Pain in the Elderly: A Review of Current and Upcoming Novel Therapeutics

Background: A significant proportion of the elderly are affected by chronic pain, resulting in a decreased quality of life. Opiate use has become increasingly common in older adult patients. This article reviews both well-established current and novel therapies for management of chronic pain in older adults. Areas of Uncertainty: The number of studies involving management of chronic pain in elderly patients is limited. Managing pain alongside multiple chronic, comorbid conditions presents therapeutic and appropriate drug dosing challenges. Therapeutic Advances: Nonsteroidal anti-inflammatory drug nano-formulations have shown promise in clinical trials. These new formulations have similar efficacy to oral nonsteroidal anti-inflammatory drugs, while minimizing adverse effects. TRV130, a new targeted opioid, selectively activates the analgesic pathway of the mu-opioid receptor. The drug has been proven to have analgesic effects similar to morphine with less opioid-induced adverse effects. Mixed opioids agonists, targeting the mu and ORL1 receptors, may prove superior among the opioid class given their effectiveness, improved safety profile, and low abuse potential. In addition, there is ongoing research assessing reduction of pain by targeted and peripherally restricted cannabinoids, attempting to limit activation of the central receptors responsible for addiction and psychotomimetic effects. Conclusions: Management of chronic pain in older adults remains challenging with current medication regimens. In facing the opiate epidemic, providers must use multicomponent strategies to find the most effective and safest combinations of pain medications to achieve adequate pain control. Regardless of the variety and complexity of pain medications available, prescribing physicians should start with low doses, titrate slowly, and monitor pain control frequently. Treating chronic pain is a complex and difficult issue that hopefully will become more manageable as pain medication regimens improve and new therapeutics are developed.

Liposomes containing cholesterol and mitochondria-penetrating peptide (MPP) for targeted delivery of antimycin A to A549 cells

•Mitochondria are exclusively employed to produce energy required for the vital metabolic functions of the cell. However, mitochondria also play a key role in mammalian cell death. Dissipation in the mitochondria membrane potential causes cell death. Therefore, in cancer therapy, mitochondria are a novel target. Herein, we developed a nano-formulation of Antimycin A specifically targeted towards mitochondria and lung cancer; A549 cell. The liposomes were prepared using cholesterol and a mitochondria-penetrating peptide (MPP) having a phenylalanine-arginine-phenylalanine-lysine (FRFK) peptide sequence. The FRFK peptide was synthesized using solid phase peptide synthesis (SPPS) and contained cholesterol in the N-terminal end of the phenylalanine (Chol-FRFK). The synthesized material was confirmed using 1H NMR, Fourier transform infrared spectroscopy (FT-IR) and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI TOF/MS). 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and Chol-FRFK, at a molar ratio of 1:1, were used for liposomal (Chol-FRFK/D) formulations; the sizes of the liposomes were confirmed using dynamic light scattering (DLS). Cytotoxicity was evaluated in A549 cells. Cellular uptake and mitochondria targeting were confirmed by flow cytometry and confocal microscopy, respectively. Antimycin A, a hydrophobic and mitochondrial electron transporter inhibitor was encapsulated into the Chol-FRFK/D liposomes. Our results indicate that Chol-FRFK/D liposomes may potentially be used for the nano-formulation of cytotoxic drugs and enhancing their bioavailability in cancer therapy.

Application of gold nanoparticles for improved drug efficiency

Due to increasing resistance of microorganisms towards current antibiotics, there is a need for new or enhanced antibiotics. Nanotechnology is a technology that enhances the use of gold nanoparticles (AuNP) in area of medical applications, especially as a drug carrier for targeted drug delivery. In this research, AuNPs was synthesized using biological method via bioreduction of Piper guineense aqueous leaf extract on tetra gold chloride, characterized using UV–Vis spectrophometer, DLS, TEM/EDS and FTIR. The synthesized AuNPs was covalently functionalized with polyethylene glycol and encapsulated with Lincomycin and in vitro dissolution methods was used to evaluate the potential performance of the formulated nanodrug. The nanodrug has highest release efficiency at the 9th minutes (23.4 mg ml−1 for 40 °C) and (29.5 mg ml−1 for 60 °C) compared with the non-nanodrug. The antibacterial potential of the nanodrug was seen on the gram-positive bacteria of Staphylococcus aureus and Streptococcus pyogenes with highest inhibitions of 18 mm (at 40 °C) and 16 mm (at 60 °C) for S. aureus, and 16 mm for S. pyogenes (both at 40 °C and 60 °C). The bacteria growth inhibition continued and lasted for 15 min, while that of non-nanodrug lasted for 9 min with lesser growth inhibition compared to the formulated nanodrug. This work shows that the presence of the AuNPs increased the release efficiency of lincomycin even at a lower concentration and also bacteria growth inhibition thereby suggesting the effectiveness of the nanodrug formulation.

Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages.

New treatments and novel drugs are required to counter the growing problem of drug-resistant strains of Mycobacterium tuberculosis (M.tb). Our approach against drug resistant M.tb, as well as other intracellular pathogens, is by targeted drug delivery using nanoformulations of drugs already in use, as well as drugs in development. Among the latter are gallium (III) (Ga)-based compounds. In the current work, six different types of Ga and rifampin nanoparticles were prepared in such a way as to enhance targeting of M.tb infected-macrophages. They were then tested for their ability to inhibit growth of a fully pathogenic strain (H37Rv) or a non-pathogenic strain (H37Ra) of M.tb. Encapsulating Ga in folate- or mannose-conjugated block copolymers provided sustained Ga release for 15 days and significantly inhibited M.tb growth in human monocyte-derived macrophages. Nanoformulations with dendrimers encapsulating Ga or rifampin also showed promising anti-tuberculous activity. The nanoparticles co-localized with M.tb containing phagosomes, as measured by detection of mature cathepsin D (34 kDa, lysosomal hydrogenase). They also promoted maturation of the phagosome, which would be expected to increase macrophage-mediated killing of the organism. Delivery of Ga or rifampin in the form of nanoparticles to macrophages offers a promising approach for the development of new therapeutic anti-tuberculous drugs.

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy.

The development of stable and long-circulating liposomes provides protection of the drug cargo from degradation and increases tumor drug delivery, leading to the design of liposome formulations with great potential in cancer therapy. However, despite the sound pharmacologic basis, many liposomal as well as other nanoparticle-based drug formulations have failed to meet regulatory criteria for approval. The question that arises is whether we have missed key liposome–host interactions that can account for the gap between the major pharmacologic advantages in preclinical studies and the modest impact of the clinical effects in humans. We will discuss here the nanoparticle–immune system interactions that may undermine the antitumor effect of the nanodrug formulations and contribute to this gap. To overcome this challenge and increase clinical translation, new preclinical models need to be adopted along with comprehensive immunopharmacologic studies and strategies for patient selection in the clinical phase.

Current HPLC Methods for Assay of Nano Drug Delivery Systems.

In nano drug formulations the mechanism of release is a critical process to recognize controlled and targeted drug delivery systems. In order to gain high bioavailability and specificity from the drug to reach its therapeutic goal, the active substance must be loaded into the nanoparticles efficiently. Therefore, the amount in biological fluids or tissues and the remaining amount in nano carriers are very important parameters to understand the potential of the nano drug delivery systems. For this aim, suitable and validated quantitation methods are required to determine released drug concentrations from nano pharmaceutical formulations. HPLC (High Performance Liquid Chromatography) is one of the most common techniques used for determination of released drug content out of nano drug formulations, in different physical conditions, over different periods of time. Since there are many types of HPLC methods depending on detector and column types, it is a challenge for the researchers to choose a suitable method that is simple, fast and validated HPLC techniques for their nano drug delivery systems. This review's goal is to compare HPLC methods that are currently used in different nano drug delivery systems in order to provide detailed and useful information for researchers.

Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer

Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer

Plant latex capped colloidal silver nanoparticles: A potent anti-biofilm and fungicidal formulation

Abstract We report a completely green, cheap and convenient route for the fabrication of highly stable silver nanocolloid from aqueous silver nitrate using latex of two different plant Jatropha curcas and Lannea grandis . The existence of silver nanoparticle has been proved by UV–Vis spectroscopy, electron diffraction and energy dispersive X-ray (EDX) analysis. The transmission electron microscopy (TEM) images show relatively higher polydispersity with average diameter 47.0 ± 2.0 nm of nanoparticle synthesized by latex of J. curcas where as latex of L. grandis generated highly monodisperse spherical particle having average diameter 7.6 ± 0.5 nm. The Fourier transform infrared (FTIR) spectra and HRTEM image demonstrate that the components of latex interacted with the surface of silver nanoparticle to make a thin layer of coating on the metal. The as-synthesized silver nanocolloid is a highly stable dispersion which exhibited no precipitation even after one year of storage. The cyto-toxicity of the nanocolloid has been tested out by hemolytic study of goat red blood corpuscles. Furthermore, we also tested the antifungal activity of this low-cytotoxic silver nanocolloid against plankotonic cell as well as biofilm of Candida albicans by spectrophotometric and microscopic (light microscopy and scanning electron microscopy) analysis. Our finding demonstrates that the bio-fabricated silver nanocolloid can be used as promising nano-drug formulation to combat against fungal infections.